Sovelis LLC was founded to develop and commercialize high throughput, innovative assay platforms for detecting abnormal heart rhythm (arrhythmia) conditions.
A major public health concern in recent years has been increasing reports of adverse cardiac events, including sudden cardiac death (heart attack), that have been associated with the use of non-cardiac drugs. To address this public health concern, Sovelis LLC is leveraging innovative developments in cellular assays with greater than 40 years experience understanding the cellular and molecular causes of cardiac arrhythmias.
To schedule an appointment or find out more about the services we offer, please call 617 297-2863 or send us an email.
Or use our contact form.
Read all news and events.